Abstract
OBJECTIVE: To examine changes in suicidality following hormone therapy (HT) among transgender and gender-diverse adolescents and young adults.
STUDY DESIGN: A retrospective chart review was conducted at a multidisciplinary gender health clinic with 432 patients (mean follow-up = 679 days) completing the Ask Suicide-Screening Questions before and after treatment initiation. A repeated-measures ANCOVA assessed within-person changes in suicidality over time, adjusting for age at treatment and treatment duration.
RESULTS: Suicidality significantly declined from pretreatment to post-treatment (F[1, 426] = 34.63, P < .001, partial η 2 = 0.075). This effect was consistent across sex assigned at birth, age at start of therapy, and treatment duration.
CONCLUSIONS: HT was associated with clinically meaningful reductions in suicidality over time, extending prior findings with a larger sample and longer follow-up. These study findings provide clinical evidence supporting the mental health benefits of timely access to HT in this population.
| Original language | English (US) |
|---|---|
| Article number | 114883 |
| Pages (from-to) | 114883 |
| Journal | Journal of Pediatrics |
| Volume | 289 |
| Early online date | Nov 1 2025 |
| DOIs | |
| State | E-pub ahead of print - Nov 1 2025 |
Keywords
- adolescent
- estrogen
- gender dysphoria
- gender-affirming hormones
- testosterone
- transgender
- youth
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health